HBC Hofseth Biocare

Hofseth Biocare ASA: First Quarter 2020 Financial Report

Hofseth Biocare ASA: First Quarter 2020 Financial Report

HBC had operating revenues of NOK 18.5m (NOK 14.7m) in the first quarter of 2020. Cost of Goods Sold (CoGS) amounted to NOK 6.2m (NOK 10.9m) in the period. Operational profit (EBITDA) for the first quarter 2020 was negative NOK 10.2m (negative NOK 12.9m). Net financial items in the first quarter were negative NOK 1.9m (negative NOK 1.3m). Loss before tax was NOK 17.9m in the quarter, compared to a loss of NOK 20.6m during first quarter 2019.

Cash and cash equivalents decreased by NOK 27.1m during the quarter, leaving total holding of cash and cash equivalents at NOK 67.5m by the end of the period.

Total assets for HBC were NOK 293.7m at the end of first quarter of 2020 (NOK 245.1m). Deferred tax assets are not posted in the balance sheet. Estimated value is NOK 147.6m. Total equity amounted to NOK 122.8m (NOK 66.8m) corresponding to an equity ratio of 41.8 % (27.3 %) for the group.

HIGHLIGHTS IN THE FIRST QUARTER 2020

  • In January, HBC signed a new credit facility of up to NOK 37m for working capital needs related to future sales contracts.
  • In March, HBC signed a comprehensive distribution contract with Prinova Europe. The agreement is a European exclusive distribution contract for branded marine products.
  • On March 23rd HBC completed a private placement towards Chief Science Officer Dr. Bomi Framroze, through issuance of 3,253,370 new shares and Dr. Framroze now holds a total of 5 million shares in HBC.
  • Preclinical research with OmeGo® demonstrates potential to target eosinophil-driven illnesses including steroid-resistant asthma.

Please find the First Quarter 2020 Financial Report attached.

For further information, please contact:

James Berger, Head of Investor Relations & Strategy of Hofseth BioCare ASA

Phone:

E-mail:

Jon Olav Ødegård, CFO of Hofseth BioCare ASA

Mob:

E-mail:

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that develops high-value ingredients and finished products. Ingredients are further developed into discovery and pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates are development towards a Gastro-Intestinal (GI) Protective Medical Food, Medical Food to help treat age-related Sarcopenia, and future phase 1 studies on treatment of Anemia and NEC-IBD with Salmon Protein Hydrolysate fractions.

The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, Chicago, Mumbai, Palo Alto and Tokyo.

HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at hofsethbiocare.com and facebook.com/hofsethbiocare

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act

Attachment

EN
15/05/2020

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on c...

Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on completion of Private Placement NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the "Company") regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 throug...

December 15, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC"), has subscribed for 368,320 Offer shares in the Subsequent Offering and Mr. Baldegger will hold 3,616,296 shares in HBC after the share capital is registered, equal to approximately 0.92 % of the total outstanding A-shares with voting rights.  For further information, contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: E-mail: This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/20...

November 21, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING

Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the "Company") regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 through issuance of up to 16,666,666 new ordinary share...

November 21, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Extraordinary General Meeting completed

Hofseth BioCare ASA: Extraordinary General Meeting completed Hofseth BioCare ASA held an Extraordinary General Meeting on 20 November 2025. All proposals were resolved as presented in the notice issued on 30 October 2025. The minutes from the Extraordinary General Meeting are attached. For further information, please contact:Jon Olav Ødegård, CEO at HBCE-mail: About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmo...

November 20, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFF...

Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFFERING NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcements by Hofseth BioCare ASA ("HBC" or the "Company") on 7 November 2025 regarding the terms of a subsequent offering of up to 16,666,666 new shares (...

November 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch